Experts have identified three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients. The cost-cutting proposals call for changes in routine clinical practice involved in end-of-life care, medical imaging, and drug pricing.
Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.
A recent study has found that, within the Asian population, the frequency of epidermal growth factor receptor mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking.
The chemical composition of commonly used chemotherapy drugs can be altered so that they only become active when they come into contact with palladium, and cancer patients could one day experience fewer side effects from chemotherapy since this discovery opens the door for more targeted treatments.
A group of researchers discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
For women with breast cancer, incorporating yoga into radiotherapy is associated with a lasting improvement in quality of life.
Grape seed can aid the effectiveness of chemotherapy in killing colon cancer cells as well as reducing chemotherapy side effects, according to new research.
A panel of 55 genes, almost all of which are impacted by the loss of a particular protein, appears to predict if breast cancer will become invasive, leading to poorer survival, according to new research.
Rates of cancer screening and provider counseling are currently below the Healthy People (HP) 2020 targets, according to a study.
The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.
Results from PROCEDE 500, a clinical utility study with the Prolaris test, demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.
Therapies specifically targeting the molecular profile of non-small cell lung cancer (NSCLC) with mutated KRAS, a cancer-causing protein, are the most effective treatment strategies for patients with NSCLC.
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
After a response to initial chemotherapy, treatment with radiotherapy and surgical removal of the breast tumor and nearby lymph nodes do not provide any additional benefit to patients with metastatic breast cancer.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|